USPTO issued patent US12590057B2 to Theracryf PLC on March 31, 2026, covering crystalline complexes of sulforaphane and alpha-cyclodextrin. The patent includes 15 claims and covers pharmaceutical compositions comprising the complexes, methods for their manufacture, and the use of said complexes as a medicament. CPC classifications indicate applications in cancer treatment (A61P 35/00), drug formulations (A61K 9/1682, A61K 9/205), and combination therapies (A61K 45/06). No compliance actions or deadlines apply. Patent holders and competitors should review the claims for freedom-to-operate considerations and potential licensing opportunities.